Medicaid
Children's Health Insurance Program

Provider update

Updates to *AIM Specialty Health Musculoskeletal Clinical Appropriateness Guidelines*

Summary of change:

Effective for dates of service on and after September 11,2022, the following updates will apply to the *AIM Specialty Health (AIM®) Musculoskeletal Clinical Appropriateness Guidelines*. As part of the AIM guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe, and affordable healthcare services.

Updates by guideline

Spine surgery:

- **Lumbar disc arthroplasty** — added indication for second-level lumbar disc arthroplasty when using a second-level FDA-approved implant
- **Lumbar discectomy** — removed exclusion for annular closure devices (**Note:** Medical necessity of the implant is determined by health plan medical policy.)
- **Lumbar fusion** — removed exclusion for anterior lumbar interbody fusion for indirect lumbar decompression in the absence of instability
- **Cervical decompression with or without fusion** — added criteria for when revision or replacement may be medically necessary
- **Cervical disc arthroplasty** — added criteria for when revision or replacement may be medically necessary
- **Two-level cervical disc arthroplasty** — added indication for second-level arthroplasty when prior arthroplasty already performed
- **Lumbar disc arthroplasty** — added requirement to manage underlying psychiatric disorder; add contraindications, including prior fusion, poorly managed psychiatric disorder, chronic radiculopathy; add exclusion for prior lumbar fusion
- **Scheurmann's kyphosis** — removed *associated neurological deficits* as a clinical consideration
- **Scoliosis** — expanded indication to include thoracic for progressive adolescent idiopathic scoliosis; increased Cobb angle for skeletally mature patients to greater than 50 degrees
  Spinal stenosis — required surgeon's interpretation of flexion-extension lateral spine X-ray documented in the medical record; added indications for recurrent stenosis, adjacent-level stenosis after a prior fusion, and planned indirect decompression via anterior approach decompression via anterior approach

Joint surgery:

- **Total shoulder arthroplasty** — added fracture indication for total shoulder arthroplasty (although reverse total shoulder arthroplasty is preferred) to align with American Academy of Orthopedic Surgeons (AAOS) feedback

* AIM Specialty Health® is an independent company providing some utilization review services on behalf of Amerigroup Iowa, Inc. Availity, LLC is an independent company providing administrative support services on behalf of Amerigroup Iowa, Inc.

- **Total shoulder arthroplasty** — added exception for Kellgren-Lawrence grade 4 to be consistent with total knee and total hip arthroplasty
- **Hemiarthroplasty** — added indications for hemiarthroplasty for glenohumeral arthritis with irreparable rotator cuff and for malignancy involving the glenohumeral joint or surrounding soft tissue
- **Reverse shoulder arthroplasty** — added indication when glenoid bone stock inadequate to support anatomic glenoid prosthesis
- **Labrum repair** — removed requirement that MRI-demonstrated Superior Labrum from Anterior to Posterior tear (SLAP) lesion is traumatic in nature
- **Adhesive capsulitis** — matched requirements in knee arthroscopy; reduce timeframe of conservative management to six weeks postsurgery for lysis of adhesions/capsular release and MUA
- **Total knee arthroplasty** — added patellofemoral osteoarthritis as an indication for total knee arthroplasty
- **Knee arthroscopy** — new indication for abrasion arthroplasty/microfracture
- **Knee/arthroscopically assisted lysis of adhesions** — removed 12-week postsurgery requirement
- **Knee/manipulation under anesthesia** — removed 12-week postsurgery requirement
- **Treatment of osteochondral defects** — removed BMI 35 or less from patient selection criteria
- **Autologous chondrocyte implantation** — added contraindications from MACI® package insert, including severe osteoarthritis, inflammatory joint disease, knee surgery other than biopsy, or MACI preparation, and inability to cooperate with postoperative rehab program

Small-joint surgery:

- **Hallux rigidus** — added criteria for select implant arthroplasties in great toe; remove exclusion for percutaneous osteotomy
- **Hallux valgus/bunionette** — removed exclusion for implant arthroplasties
- **Lesser toe deformities** — removed exclusions for implant arthroplasties and intramedullary fixation devices
- **First metatarsophalangeal joint arthrodesis** — removed requirement for six months of symptoms
- **First metatarsophalangeal joint arthroplasty** — new indication
- **Hallux rigidus/exclusions** — clarified specific types of excluded implants; excluded metatarsophalangeal joint arthroplasties for any other indications; excluded peripheral neuropathy/Charcot joint

Sacroiliac (SI) joint fusion:

- Expanded indication to include any FDA-approved minimally invasive/percutaneous SI joint fusion device with fixation
- Require a trial of at least one therapeutic intra-articular SI joint injection
- New criteria for revision minimally invasive SI joint fusion
- Add exclusion for posterior (dorsal) minimally invasive SI joint fusion procedures using only bone grafts and no internal fixation device

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

- Access AIM's ***Provider****Portal*SM directly at **https://www.providerportal.com**:
  - **Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.**
- Access AIM via the Availity* Portal at **https://www.availity.com**
- Call the AIM Contact Center toll-free number at **833-305-1808**, Monday through Friday, from 7 a.m. to 7 p.m. Central time

If you have questions related to guidelines, please contact AIM via email at aim.guidelines@aimspecialtyhealth.com. Additionally, you may access and download a copy of the current and upcoming guidelines at **https://aimspecialtyhealth.com/resources/clinical-guidelines**.

Email is the quickest and most direct way to receive important information from Amerigroup Iowa, Inc.

To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (**https://bit.ly/2ZkhcsB**).